|Articles|August 10, 2010

EGA Talks Biosimilars

The European Generic Medicines Association's Director for Scientific Affairs, Suzette Cox, talks to us about the environment for biosimilars.

Click here.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Legal Risk in a Rumored AstraZeneca-BMS Deal: Q&A with Ron Lanton

ByNicholas Jacobus,Ron Lanton

August 6th 2026

FDA Approves Moderna's mRNA-Based Flu Vaccine

ByPharmaceutical Executive Editorial Staff

August 6th 2026

Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report

ByNicholas Jacobus

August 5th 2026

CSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in China

ByNicholas Jacobus

August 5th 2026

For complex biologics, such as multispecific antibodies or antibody drug conjugates, the modality itself is a coordination puzzle. Credit: Stock.Adobe.com/anamejia18.

Why Biologics R&D Platforms Are Failing Complex Modalities and What Must Change

ByChristian Olsen

August 3rd 2026

EGA Talks Biosimilars

Related Content

Legal Risk in a Rumored AstraZeneca-BMS Deal: Q&A with Ron Lanton

FDA Approves Moderna's mRNA-Based Flu Vaccine

Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report

CSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in China

Why Biologics R&D Platforms Are Failing Complex Modalities and What Must Change

Trending on PharmExec

FDA Grants Accelerated Approval to Tudriqev in Combination with Nivoumab for Advanced Melanoma

Legal Risk in a Rumored AstraZeneca-BMS Deal: Q&A with Ron Lanton

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million

Amazon Pharmacy Launches GLP-1 Delivery Service

Your Questions Answered: The Biggest Pharma Stories of the Week of August 3-7, 2026